Drug intelligence / Profile preview

TJ099

Development stage: Preclinical
Lead developer: Tuojie Biotech
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

TJ099 is a preclinical RNA interference (RNAi) therapeutic candidate being developed by Tuojie Biotech for the treatment of Parkinson's Disease. The drug utilizes small interfering RNA (siRNA) technology to selectively silence the expression of a target gene implicated in the pathogenesis of the disease. By degrading the target mRNA, TJ099 aims to reduce the production of proteins that contribute to neurodegeneration and the motor symptoms of Parkinson's. As of 2024, the program is in the Pre-Clinical Candidate (PCC) stage of development.

Beyond the preview

Go deeper on TJ099.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TJ099.

Explore the full profile